Omega-3 Supplementation for Smell Dysfunction

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Omega-3 supplementation has been shown to have neuroprotective and potentially anti-inflammatory properties in both central and peripheral nerve injuries. The investigators are studying to see if omega-3 supplementation will affect olfactory (smell) function in patients with olfactory dysfunction following endoscopic removal of pituitary tumors.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05855369` - Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss	Phase 2/Phase 3
Recruiting	`NCT05364125` - Olfactory Training on Smell Dysfunction Patients in HK	N/A
Recruiting	`NCT06456008` - Prospective Registery of Smell/Taste Clinic Ear/Nose/Throat
Not yet recruiting	`NCT05104424` - The Study of Quadruple Therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation for Post COVID-19 Smell and Taste Dysfunctions	Phase 1

NCT number	NCT02529332
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	N/A
Start date	September 2014
Completion date	April 2018

Omega-3 Supplementation for Smell Dysfunction

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms